Mylan shares to rally nearly 60 percent as EpiPen controversy fades: Raymond James

CNBC: Top News

Raymond James on Monday upgraded shares of Mylan to strong buy from market perform, citing valuations that have reached a multidecade low.

view CNBC: Top News